Neurocrine Biosciences has introduced a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the leading VMAT2 inhibitor for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease. This new INGREZZA® SPRINKLE (valbenazine) formulation is now available through the same specialty and local pharmacies that distribute the original INGREZZA capsules.
“With INGREZZA® SPRINKLE, we provide an alternative for patients who have difficulty swallowing pills, making treatment more accessible and manageable,” said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. The new formulation allows patients to sprinkle the granules on soft foods like applesauce, yogurt, or pudding, easing the administration process.
Both INGREZZA and INGREZZA SPRINKLE offer a straightforward dosing regimen of one capsule daily with no need for complex dose adjustments. The new sprinkle version maintains the same dosing options of 40 mg, 60 mg, and 80 mg, which can be tailored by healthcare providers based on individual response.
“Swallowing issues are common among those with chorea associated with Huntington’s disease,” noted Katie Jackson, President of Help 4 HD International. “This new formulation helps alleviate the burden of pill swallowing, particularly as the disease progresses.”
Neurocrine Biosciences received FDA approval for INGREZZA SPRINKLE on April 30, based on its bioequivalence and tolerability compared to INGREZZA capsules. The cost of INGREZZA SPRINKLE is aligned with INGREZZA, and the INBRACE® Support Program offers assistance with product support, prescription fulfillment, and financial aid for eligible patients.
For more information, including details about INGREZZA SPRINKLE and the INBRACE® Support Program, visit INBRACESupportProgram.com/INGREZZAPatient/.
About Tardive Dyskinesia (TD) and Chorea Associated with Huntington’s Disease
TD is a movement disorder marked by uncontrollable movements of the face, torso, or limbs, often due to long-term use of certain antipsychotic medications. Chorea is a symptom of Huntington’s disease characterized by irregular, involuntary movements that can affect coordination, gait, and swallowing.
About INGREZZA®
INGREZZA is a VMAT2 inhibitor used to treat TD and chorea associated with Huntington’s disease. The medication is available in both standard and sprinkle formulations, offering flexibility for patients with difficulty swallowing.
Important Safety Information
INGREZZA and INGREZZA SPRINKLE may cause serious side effects, including depression, allergic reactions, and heart rhythm problems. Patients should consult their healthcare provider before starting treatment and report any adverse effects. Full prescribing information is available.
Neurocrine Biosciences
Neurocrine Biosciences is dedicated to developing treatments for neurological and neuropsychiatric disorders. The company’s portfolio includes FDA-approved treatments for various conditions and a robust pipeline of clinical developments.
For more information, visit neurocrine.com or follow the company on LinkedIn, X (formerly Twitter), and Facebook.
Trademarks
INGREZZA® and NEUROCRINE are registered trademarks of Neurocrine Biosciences, Inc.
